Bacterial and fungal coinfections among patients with COVID-19 in Zanjan, Northwest of Iran; a single-center observational with meta-analysis of the literature

Hamid Morovati1, Saba Eslami2, Hesam Farzaneh Bonab3, Mohammad Kord4, Sima Darabian1

1Department of Parasitology and Mycology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
2Central Research Laboratory, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
3Department of Medical Parasitology and Mycology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
4Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

Received: July 2022, Accepted: September 2022

ABSTRACT

Background and Objectives: There is a poor understanding about the prevalence and characteristics of secondary bacterial and fungal infections among Coronavirus diseases 2019 (COVID-19) superinfection in hospitalized patients.

Materials and Methods: Four hundred COVID-19-proven patients were enrolled in this study. Nasal swabs for molecular assay (Real-time PCR) and sputum samples for further microbiological assays were collected. Following a broad-spectrum search, a meta-analysis was performed using StatsDirect software (version 2.7.9) according to the DerSimonian and Laird method applying the random-effects models.

Results: Streptococcus spp. (21.5%) and Staphylococcus spp. (16.7%) had the highest prevalence of bacterial coinfection among the COVID-19 patients, while Acinetobacter spp. had the lowest prevalence (4.2%). Among fungal coinfections, Candida albicans was the most prevalent (6.7%), and Aspergillus spp. was the lowest (2%). Males, elderly patients, patients with a history of underlying diseases and drug use, patients who showed acute clinical symptoms, and patients with a prolonged hospital stay had a higher incidence of secondary infections (P-value < 0.05). The pooled prevalence for bacterial and fungal coinfections was 33.52% (95% CI: 18.12 to 50.98; I2: 99.4%; P-value: <0.0001).

Conclusion: We suggest designing additional research with a larger target population and diagnostic molecular analyses to depict a more realistic view of the coinfection status.

Keywords: COVID-19; Secondary infection; Nosocomial infection

INTRODUCTION

Coronavirus diseases 2019 (COVID-19) affect more than 500 million people worldwide, resulting in more than six million deaths (WHO) (1). Up to 2022, over 140,000 of 7 million positive cases have died due to this pandemic in Middle-Eastern Iran (2). A beta-named variant of COVID-19 leads to severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (3). Early symptoms of SARS-CoV-2 infection are similar to upper respiratory tract infections caused by other microorganisms and include fever, coughing, tiredness, and respiratory discomfort (4-6). Most patients with COVID-19 may have diarrhea, lethargy, myalgia, and anorexia at the outset of the disease (7). Typical symptoms include headaches, dizziness, vomiting, rhinorrhea, and nasal congestion (4-6, 8). Furthermore, the virus can cause significant complications such as respiratory distress syndrome and the involvement of many organs (9).

The broad spectrum of symptoms and their varying incidence period are the main characteristics of COVID-19 infection (6, 10-13). Co-infections of SARS-CoV-2 with bacteria, fungi, and other viruses is a crucial issue that can create a slew of complications in the diagnosis, treatment, and finally exacerbate symptoms and increase death (14, 15). According to investigations, around 5% of COVID-19 patients have COVID-19-associated bacterial (CAB) co-infections during their hospitalization period (14-17). The administration of antibiotics for hospital-acquired bacterial infections caused by *Staphylococcus* spp. and *Streptococcus* spp. is an imperative strategy for the management of hospitalized COVID-19 patients (18). The risk of COVID-19-associated fungal (CAF) co-infections, particularly those caused by *Aspergillus* and *Candida* species, is increased in the target population, especially those admitted to intensive care units (ICU), patients requiring long-term mechanical ventilation, and patients who have been hospitalized for more than 50 days (14-17).

Among hospitalized patients, differentiating COVID-19 infection from hospital-acquired and ventilator-related pneumonia is a matter (19). Additionally, hospitalized patients may develop secondary non-respiratory tract infections, such as urinary tract infections (UTI) and bloodstream infections (BSI) (20). Concurrent bacterial and fungal infections in hospitalized people with COVID-19-induced acute respiratory syndrome are poorly characterized (21). Clinically, distinguishing viral infection from the bacterial or fungal respiratory infection will be problematic (22). Because co-infection with SARS-CoV-2 might increase the effects of primary disease, careful consideration is a critical clinical necessity in patients with COVID-19 (21).

This study aimed to evaluate the prevalence of bacterial and fungal co-infections among patients with COVID-19 in Zanjan-Iran. Also, the meta-analysis of the literature is aimed to compare the results of the current study with previous studies.

**MATERIALS AND METHODS**

**Study settings and data collection.** This single-center observational study was conducted in the specialized COVID-19 hospital between February 2020 and February 2021 in Zanjan-Iran.

The following parameters were included in the data collection checklist based on the hospital records: age, gender, history of underlying disease, history of drug use, length of hospital stay, the result of Real-time polymerase chain reaction (PCR) test for SARS-Cov-2 (if available), clinical evidences of secondary infection(s) (including fever, nausea, vomiting, stiff neck, headache, seizures, and other nonspecific symptoms), the color of sputum, and the culture results of sputum (if available) for the diagnosis of secondary infection. This study was approved by the Ethics Committee of Zanjan University of Medical Sciences Code number:IR.ZUMS.REC.1400.179.

**Patients and samples.** A total of 1390 suspected COVID-19 patients were admitted to the COVID-specialized hospital. Additionally, laboratory evidences of secondary bacterial or fungal infections were captured. Patients with negative Real-time PCR (unconfirmed) were excluded from further analysis.

**Assessment of COVID-19 infection by Real-time PCR test.** Positive Real-time PCR results were the major inclusion criteria for this study. In this regard, obtained/ordered nasal swab samples were collected from the admitted patients, and RNA extraction and cDNA synthesis were carried out using their kits (YTA; Yekta Tajhiz Azma; Tehran-Iran). Real-time PCR was carried out in triple reactions using Probe qPCR Master Mix (YTA; Yekta Tajhiz Azma; Tehran-Iran). The 2019-nCoV N1-P primer and probe pairs (FAM-ACC CCG CAT TAC GTT TGG ACC-BHQ1; FAM-ACC CCG CAT /ZEN/ TAC GTT TGG TGG ACC-3IABkFQ) were selected for capturing SARS-Cov-2 during Real-Time processes (CDC).

**Microbiological diagnosis of bacterial and fungal pathogens.** To detect bacterial and fungal pathogens among patients with clinical signs and symp-
toms, sputum samples were obtained or ordered and cultured on Sabouraud Dextrose Agar (SDA) with chloramphenicol for fungal and Blood agar 5%, Chocolate agar, and MacConkey agar bacterial coinfections. Results were categorized as no sputum obtained, ordered/not done, without growth, contaminated, or based on the recovered organism(s). The cultures were incubated for 3-7 days at 32-37°C. Moreover, potassium hydroxide (KOH), slide culture (for molds), and germ tube production tests for fungal and Gram staining for all specimen were carried out. Moreover, the results of the biochemical tests for bacterial pathogens were recorded.

Meta-analysis and statistical analysis of data. We searched related databases between April 2021 and May 2022 for studies that reported data about COVID-19-associated coinfections. We developed a broad search strategy to identify studies that reported COVID-19-associated coinfections. In our systematic review, the search terms "Coronavirus disease," "COVID-19," "SARS-CoV-2 infection," "Bacterial," "Fungal," "Coinfection,"and related terms and words for relevant studies published in PubMed, Web of Science, Scopus, Google Scholar, LitCovid, and ProQuest between April 2021 and May 2022 were used (Fig. 1). No linguistic or geographical limits were applied. We hand-searched bibliographies of all recovered articles for potentially eligible studies and contacted corresponding authors for published or unpublished data if needed. Inclusion criteria were as follows: COVID-19 patients proven with Real-time PCR who have positive for fungal and/or bacterial coinfections. Meta-analysis was performed using StatsDirect software (version 2.7.9) according to the DerSimonian and Laird method applying the random-effects model. We evaluated heterogeneity using the \( \chi^2 \)-based Q statistic (significant for P-value <0.1) and the I\(^2 \) statistic (>75 % indicative of "notable" heterogeneity). SPSS (version 20) software was used for analysis. The k2 or independent t-test (Mann-Whitney test) was used to explore the correlation between demographic characteristics and the frequency of laboratory findings. A significance level of 5% was considered.

RESULTS

Patients characteristics. Four hundred patients with confirmed SARS-CoV-2 were identified with secondary fungal and bacterial infections during the study period (between February 2020 and February 2021). Among them, 42% were women, and 58% were men (Table 1). Patients aged 30-75 were randomly divided into three groups: 40.5% were >60 years old, 39.3% were 50-60, and 20.3% were under 50 years old (Table 1). Furthermore, 72.5% of patients had a history of underlying disease, and 63.5% had drug administration. Fever, nausea, vomiting, stiff neck, headache, seizures, and other nonspecific symptoms are reported to occur 50.8%, 39%, 22%, 49.3%, 63%, 2.5%, and 9% of the time, respectively. As seen in Table 1, the highest and lowest rates of clinical signs and symptoms were headaches (63 %) and seizures (2.5 %). The patients' mean length of stay (LOS) in hospital wards was 6 to 10 days (64.8%). Furthermore, the sputum colors were as follows: yellow (54%), green (30%), clear (13%), and red or brown sputum in 3% of the patients (Table 1).

Characteristics of secondary bacterial and fungal infections. According to the findings, sputum cultures were positive in 72% of patients. Also, bacterial and fungal species were responsible for 63.2% and 8.8% of secondary infections, respectively. The major bacterial causative agents were as follows: Staphylococcus spp. (21.5%), Staphylococcus spp. (16.7%), Escherichia coli (8.7%), Pseudomonas pp. (7.2%), Klebsiella spp. (4.7%), and Acinetobacter spp. (4.2%). Moreover, Candida albicans (6.7%) and Aspergillus spp. (2.1%) were the dominant fungal pathogens (Table 2). The highest frequency was seen in the age group above sixty years; 75.9% of these patients had a positive culture result (69.7% bacteria and 6.2% fungi) (Table 3). Among patients aged 50 to 60, 74.5% had positive cultures (62.4% of bacteria and 12.1% of fungi) (Table 3). The findings also showed that there was a significant difference in secondary infections between men and women (P-value<0.05) (Table 3). Men had a secondary infection rate of 80.6% (66% for COVID-associated bacterial coinfections, CAB, and 14.6% for COVID-associated fungal infections, CAF), much higher than women at 60.1% (48.3% for CAB and 11.8% for CAF) (P-value< 0.05). Additionally, patients with an underlying condition had a significantly higher secondary infection rate than those without any underlying diseases (total: 84.1%; CAB: 72.8%; CAF: 11.3%, P-value <0.05).

Moreover, patients with a drug administration had
a significantly higher prevalence of secondary infections (Total: 80.7%; CAB: 75.2%; CAF: 7.5%, P-value< 0.05) (Table 3). Also, patients who spent more than 11 days in the hospital were more susceptible to develop coinfections (total: 95.5%, CAB: 54.6%, CAF: 40.9%, P-value< 0.05) (Table 3). We found a significant difference in clinical symptoms, including fever, nausea, vomiting, headache, neck cramps, and seizures, based on the frequency of secondary infection (P-value: 0.05) (Table 3). According to the findings, patients who experienced the following symptoms were more prone to develop secondary infections (P-value<0.05); fever (81.7%), nausea (64.3%), vomiting (68.2%), headache (94.6%), neck pains (77.2%), and seizures (2.5%) (Table 3).

**Meta-analysis.** Our meta-analysis included nine eligible studies in the field plus the current study (total of ten studies) (23-31) after an electronic search and removing duplicate and irrelevant records. The distribution of each survey by country is as follows: Spain, USA, Iran, Saudi Arabia, UK, Italy, a multicenter study from Italy, Croatia, Serbia, Slovenia, and two studies from Turkey.

In this analysis, 11,269 patients were hospitalized with SARS-CoV-2. A total of 1,387 CAB coinfections were reported in nine eligible studies. The pooled prevalence for CAB coinfections was 24.08% (95% CI: 15.16 to 34.32; I2: 99.1%; P value: <0.0001) (Tables 4 and 5; Figs. 2 and 3). Also, 475 CAF coinfections were reported in six eligible studies. The pooled prevalence for CAF coinfections was 6.46% (95% CI: 3.47 to 10.27; I2: 95.9%; P value: <0.0001) (Tables 4 and 6; Figs. 4 and 5). The overall prevalence
Table 1. Demographic and clinical characteristics of patients with SARS-CoV-2 and bacterial-Fungal coinfections.

| Characteristic                          | Category | Frequency (N = 400) | Percentage | P-value |
|-----------------------------------------|----------|---------------------|------------|---------|
| Age (years)                             | >60      | 162                 | 40.5%      | 0.03    |
|                                         | 50-60    | 157                 | 39.3%      | 0.02    |
|                                         | <50      | 81                  | 20.3%      | 0.01    |
| Gender                                  | Female   | 168                 | 42%        | 0.02    |
|                                         | Male     | 232                 | 58%        | 0.03    |
| Comorbidities                           | Yes      | 290                 | 72.5%      | 0.02    |
|                                         | No       | 110                 | 27.5%      | 0.04    |
| Underlying Diseases                     | Yes      | 254                 | 63.5%      | 0.01    |
|                                         | No       | 146                 | 36.5%      | 0.01    |
| Clinical signs and symptoms             | Fever    | 203                 | 50.8%      | 0.01    |
|                                         | Nausea   | 156                 | 39%        | 0.01    |
|                                         | Vomiting | 88                  | 22%        | 0.01    |
|                                         | Stiff neck | 197              | 49.3%      | 0.02    |
|                                         | Headache | 252                 | 63%        | 0.02    |
|                                         | Seizures | 10                  | 2.5%       | 0.02    |
|                                         | Other symptoms | 36                | 9%         | 0.02    |
| LOS (days)                              | 3-5      | 119                 | 29.8%      | 0.001   |
|                                         | 6-10     | 259                 | 64.8%      | 0.001   |
|                                         | >11      | 22                  | 5.5%       | 0.001   |
| Sputum color                            | yellow   | 225                 | 54%        | 0.01    |
|                                         | green    | 120                 | 30%        | 0.01    |
|                                         | clear    | 52                  | 13%        | 0.01    |
|                                         | red or brown | 3                | 0.75%      |         |

Table 2. Prevalence of bacterial and fungal coinfections isolated from respiratory samples.

| Characteristic                          | Category                        | Frequency (N = 400) | Percentage | P-value |
|-----------------------------------------|---------------------------------|---------------------|------------|---------|
| Sputum culture results                  | Positive                        | 288                 | 72%        | 0.04    |
|                                         | Negative                        | 112                 | 28%        | 0.04    |
| Isolated pathogen                       | Bacterial                       | 253                 | 63.2%      | 0.001   |
|                                         | Fungal                          | 35                  | 8.8%       | 0.001   |
| Bacteria                                | *Streptococci* spp.             | 86                  | 21.5%      | 0.005   |
|                                         | *Staphylococcus* spp.           | 67                  | 16.7%      | 0.005   |
|                                         | *Escherichia coli*              | 35                  | 8.7%       | 0.001   |
|                                         | *Pseudomonas aeruginosa*        | 29                  | 7.2%       | 0.001   |
|                                         | Klebsiella spp.                 | 19                  | 4.7%       | 0.001   |
|                                         | *Acinetobacter* spp.            | 17                  | 4.2%       | 0.001   |
|                                         | *Candida albicans*              | 27                  | 6.7%       | 0.005   |
|                                         | *Aspergillus* spp.              | 8                   | 2.1%       | 0.005   |

of COVID-19-associated bacterial and fungal coinfections (CABF) in six studies which were occurred concomitantly (not in one patient) was 33.52% (95% CI: 18.12 to 50.98; 12: 99.4%; P-value: <0.0001) (Tables 4 and 7; Figs. 6 and 7).

**DISCUSSION**

During the pre-COVID era, the increase of secondary infections in hospitalized patients has been worrying. With the emergence of the COVID-19
pandemic, the importance of paying attention to secondary infections has increased. This study aims to clarify the statistics of these infections and guide doctors and public health policymakers in the optimal management of treatment and prevention of COVID-19 patients with secondary infections.

We investigate the frequency of CABF in sputum, urine, blood, and catheter samples of patients admitted to a Covid-specialized hospital in Zanjan-Iran, between February 2020 and February 2021. 58% of patients were men, and 40.5% were >60 years old. A total of 72% of sputum samples were positive for bacterial and fungal systemic infections BFSI. 63.2% of them were bacteria, and 8.8% of them were fungi. The average hospital duration was 6 to 10 days (64.8%).

Studies by Zhang et al. (32) from Shanghai and Liu et al. (33) from the USA indicated that 58% and 54% of the sputum samples were positive for BFSI, respectively. According to Liu et al., this rate increased to 64.9% following intubation (33). We resulted that Gram-positive bacteria, including *Streptococci* spp. and *Staphylococci* spp. were the most common causative agents of BFSI. Hughes et al. (34) and Russell et al. (5) conducted similar research and identified *Staphylococcus aureus* as the most common cause of CAB coinfections in the UK. In a study by Ripa et al. (20) in Italy, most of the BSIs were due to Gram-positive pathogens (76/106 isolates, 71.7%), specifically coagulase-negative *Staphylococci* spp. (53/76, 69.7%), while among Gram-negatives (23/106, 21.7%) *Acinetobacter baumannii* (7/23, 30.4%) and *Escherichia coli* (5/23, 21.7%) were predominated.

We found that the rate of BFSI increased with patients’ age. This study is in line with those of Zhang et al. (32) in China, Santis et al.(35) in Italy, and Shafarian et al.(36). They found that the risk of BFSI in COVID-19 patients rises with age due to physiological and physical circumstances and immunological disorders.

We indicated that the rates of male and female patients with secondary infection were 80.6% (66% bacteria and 14.6% fungi) and 60.1% (48.3% bacteria and 11.8% fungi). However, Zhang et al. (32) reported that the proportion of BFSI cases did not change by the patient’s gender. According to studies by Nasir et al. (37) in Iran and Gebhard et al. (38) in Switzerland, men are more susceptible to acquiring BFSIs when ICU admission rates increase. The variations between the various studies could be related to geographical changes. Another reason is that men and women have physiological and hormonal differences (39).

In contrast to the findings of Zhang et al.(32), we showed that 84.1% of the patients with underlying conditions were BFSI-positive (72.8% bacteria and 11.3% fungi). These discrepancies could be related to the smaller sample size in the Zhang study (57.89%; 22/38) compared to the current study, limiting the data's generalizability. According to a study by Santis et al. (35), 101 patients (40.7%) had BFSI with high severity and extended hospital stay. People with underlying disorders typically have a weakened immune system and are more susceptible to coinfections. According to Cullen et al. in Dublin, BFSIs were more common in hospitalized patients.
| Study | % Weight (fixed random) | Variance | Standardized Effect |
|-------|-------------------------|----------|---------------------|
| 1 | 0.10 | 0.20 | 0.30 |
| 2 | 0.20 | 0.30 | 0.40 |
| 3 | 0.30 | 0.40 | 0.50 |

Table 5. Analogous details of the eligible studies.

Table 4. Pooled prevalence, heterogeneity, and publication bias analysis results with details.
We indicated that patients having COVID-19 had more severe clinical symptoms and positive culture results indicating BFSI. This is in line with the findings of investigations by Zhang et al. and Gebhard et al. (32, 38). These findings can be explained by the fact that the secondary infection exacerbates the disease symptoms, and it is expected that the symptoms of patients with the secondary infection will be more severe than those of patients with COVID-19 alone. *Candida albicans* was the major fungus responsible for BFSI (6.7%). According to a study by White et al. in the UK (41), 1.3% of patients with COVID-19 had severe *Candida* infection. A study indicated that the prevalence of emerging multi-drug resistant *C. auris* among COVID-19 patients was 5.7% (42). Other investigations revealed that 2.2 to 12% of patients with COVID-19 had *Candida* infection.

Moreover, our results from the meta-analysis showed that bacterial coinfection occurred 2.15 times more than fungal infections among COVID-19 patients. Although they were frequently fatal causes of influenza pandemics and made viral respiratory illnesses worse, bacterial coinfections have not been thoroughly studied in individuals with coronavirus.

**Fig. 2.** Forest plot of the pooled prevalence of patients with COVID-19 and bacterial coinfections.

**Fig. 3.** Funnel plot of the pooled prevalence of patients with COVID-19 and bacterial coinfections.

with a history of drug administration (40). Patients with a history of drug use were found to have a secondary infection in 80.7% of cases (75.2% of bacteria and 7.5% of fungi). According to the findings of this study, the length of hospital stay impacts the incidence of secondary infection. This finding was in line with the results reported by Zhang et al. and Nasir et al.'s (32, 37).
Table 6. Analysis details of studies with fungal coinfections.

| Stratum | Standardized effect | Variance | % Weights (fixed, random) | Studies |
|---------|---------------------|----------|---------------------------|---------|
| 1       | 0.062568            | 0.000181 | 66.991703                 | Moradi; Nov 2021; Iran |
| 2       | 0.019934            | 0.00166  | 7.298165                  | Genç Bahçe; 15 Jan 22; Turkey |
| 3       | 0.015182            | 0.001012 | 11.973836                 | Papst; 28 Jan 2022; Slovenia-Serbia-Italy-Croatia |
| 4       | 0.189189            | 0.006734 | 1.798801                  | Arasteh; 13 Feb 2022; Turkey |
| 5       | 0.02046             | 0.002554 | 4.742293                  | Chan; 23 March 2022; UK |
| 6       | 0.160622            | 0.005168 | 2.343892                  | Ceparano; 28 March 22; Italy |
| 7       | 0.0875              | 0.002497 | 4.851311                  | Current Study |

Fig. 4. Forest plot of the pooled prevalence of patients with COVID-19 and fungal coinfections.

Fig. 5. Funnel plot of the pooled prevalence of patients with COVID-19 and fungal coinfections.

disease (COVID-19). Numerous viral respiratory tract infections frequently result in bacterial coinfection, dramatically increasing morbidity and death (43). Increasing published evidence should warn clinicians about the link between COVID-19 and invasive fungal infections (IFIs) (44). IFIs are known to increase mortality significantly and can exacerbate the clinical course of COVID-19, particularly in critically ill patients admitted to the ICU. Secondary IFIs, typically found in individuals with severe immunodeficiency, indicate that SARS-CoV-2 can overwhelm the host immune system (44, 45).

One of our study’s limitations is that we carried out a single-center investigation. Another limitation is
Table 7. Analysis details of studies with bacterial and fungal coinfections.

| Stratum | Standardized effect | Variance  | % Weights (fixed, random) | Studies                                      |
|---------|---------------------|-----------|---------------------------|----------------------------------------------|
| 1       | 0.13906             | 0.000181  | 68.218823                 | Moradi; Nov 2021; Iran                       |
| 2       | 0.134551            | 0.00166   | 7.431849                  | Genç Bahçe; 15 Jan 22; Turkey               |
| 3       | 0.184211            | 0.001012  | 12.193166                 | Papst; 28 Jan 2022; Slovenia-Serbia-Italy-Croatia |
| 4       | 0.324808            | 0.002554  | 4.82916                   | Chan; 23 March 2022; UK                     |
| 5       | 0.606218            | 0.005168  | 2.386826                  | Ceparano; 28 March 22; Italy                |
| 6       | 0.72                | 0.002497  | 4.940175                  | Current Study                                |

Fig. 6. Forest plot of the pooled prevalence of patients with COVID-19 and fungal and bacterial coinfections.

that we could not perform a cohort study due to limitations in accessibility to patients and data during the quarantine. However, we reported the status of COVID-19-associated fungal and bacterial coinfection on a large scale from northwest Iran. Also, the application of Real-time PCR and performing a comprehensive meta-analysis are other strengths of our investigation.

CONCLUSION

We showed that COVID-19 patients with secondary bacterial and fungal co-infections were mainly old-
er men having underlying diseases and patients with obvious clinical signs of respiratory failure. Bacteria were also more than half of the identified respiratory pathogens. Therefore, early detection of secondary infection, identifying high-risk patients, and determining appropriate interventions to reduce mortality is essential. Finally, similar studies supported by molecular diagnostic methods, more extensive scales, and more medical centers are recommended.

ACKNOWLEDGEMENTS

This study was supported by the Vice President of Research, Zanjan University of Medical Sciences (contract number: A-12-1346-2). The authors are grateful for the great support of the laboratory of Medical Mycology, School of Medicine, Zanjan University of Medical Sciences.

REFERENCES

1. Wang H, Paulson KR, Pease SA, Watson S, Comfort H, Zheng P, et al. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21. Lancet 2022; 399: 1513-1536.
2. Salimi R, Gomar R, Heshmati B. The COVID-19 outbreak in Iran. J Glob Health 2020; 10: 010365.
3. Chen X, Liao B, Cheng L, Peng X, Xu X, Li Y, et al. The microbial coinfection in COVID-19. Appl Microbiol Biotechnol 2020; 104: 7777-7785.
4. Carvalho-Schneider C, Laurent E, Lemaignen A, Beauvais E, Bourbou-Tournois C, Laribi S, et al. Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clin Microbiol Infect 2021; 27: 258-263.
5. Russell CD, Fairfield CJ, Drake TM, Turtle L, Seaton RA, Wootton DG, et al. Co-infections, secondary infections, and antimicrobial use in patients hospitalized with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. Lancet Microbe 2021; 2(8): e354-e365.
6. Sykes DL, Holdsworth L, Jawad N, Gunasekera P, Morice AH, Crooks MG. Post-COVID-19 symptom burden: what is long-COVID and how should we manage it? Lung 2021; 199: 113-119.
7. Salamanna F, Veronesi F, Martini L, Landini MP, Fini M. Post-COVID-19 syndrome: the persistent symp-
toms at the post-viral stage of the disease. A systematic review of the current data. Front Med (Lausanne) 2021; 8: 653516.
8. Malayala SV, Mohan G, Vasireddy D, Atluri P. A case series of vestibular symptoms in positive or suspected COVID-19 patients. Infect Med 2021; 29: 117-122.
9. Baral PK, Yin J, James MNG. Treatment and prevention strategies for the COVID 19 pandemic: A review of immunotherapeutic approaches for neutralizing SARS-CoV-2. Int J Biol Macromol 2021; 186: 490-500.
10. Garcia LF. Immune response, inflammation, and the clinical spectrum of COVID-19. Front Immunol 2020; 11: 1441.
11. Li M, Lei P, Zeng B, Li Z, Yu P, Fan B, et al. Coronavirus disease (COVID-19): spectrum of CT findings and temporal progression of the disease. Acad Radiol 2020; 27: 603-608.
12. Xu Z, Li S, Tian S, Li H, Kong L-Q. Full spectrum of COVID-19 severity still being depicted. Lancet 2020; 395: 947-948.
13. Hull JH, Wootton M, Moghal M, Heron N, Martin R, Walsted ES, et al. Clinical patterns, recovery time and prolonged impact of COVID-19 illness in international athletes: the UK experience. Br J Sports Med 2022; 56: 4-11.
14. Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, et al. Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis 2020; 71: 2459-2468.
15. Rawson TM, Wilson RC, Holmes A. Understanding the role of bacterial and fungal infection in COVID-19. Clin Microbiol Infect 2021; 27: 9-11.
16. Abdoli A. Iran, sanctions, and the COVID-19 crisis. J Med Econ 2020; 23: 1461-1465.
17. Buehler PK, Zinkernagel AS, Hofmaenner DA, Wendel Garcia PD, Acevedo CT, Gómez-Mejía A, et al. Bacterial pulmonary superinfections are associated with longer duration of ventilation in critically ill COVID-19 patients. Cell Rep Med 2021; 2: 100229.
18. Garcia-Vidal C, Sanjuan G, Moreno-Garcia E, Puerta-Alcalde P, Garcia-Pouton N, Chumbita M, et al. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol Infect 2021; 27: 83-88.
19. Paley EL. Towards understanding COVID-19: Molecular insights, co-infections, associated disorders, and aging. J Alzheimers Dis Rep 2021; 5: 571-600.
20. RIPA M, Galli L, Poli A, Oltolini C, Spagnuolo V, Mastangelo A, et al. Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors. Clin Microbiol Infect 2021; 27: 451-457.
21. Risa E, Roach D, Budak JZ, Hebert C, Chan JD, Mani NS, et al. Characterization of secondary bacterial in-
COINFECTIONS AMONG PATIENTS WITH COVID-19

fections and antibiotic use in mechanically ventilated patients with COVID-19, induced acute respiratory distress syndrome. *J Intensive Care Med* 2021; 36: 1167-1175.

22. Chirico F, Nucera G, Magnanivita N. COVID-19: protecting healthcare workers is a priority. *Infect Control Hosp Epidemiol* 2020; 41: 117.

23. Alqtainti A, Alamer E, Mir M, Alasmari A, Alshahriani MM, Asiri M, et al. Bacterial Coinfections Increase Mortality of Severely III COVID-19 Patients in Saudi Arabia. *Int J Environ Res Public Health* 2022; 19: 2424.

24. Arastehfar A, Únal N, Hoşbul T, Alper Özarslan M, Sultan Karakoyun A, Polat F, et al. Candidemia among Coronavirus Disease 2019 patients in Turkey admitted to intensive care units: a retrospective multicenter study. *Open Forum Infect Dis* 2022; 9: ofac078.

25. Bahçe YG, Acer Ö, Özüdoğru O. Evaluation of bacterial agents isolated from endotracheal aspirate cultures of Covid-19 general intensive care patients and their antibiotic resistance profiles compared to pre-pandemic conditions. *Microb Pathog* 2022; 164: 105409.

26. Ceparano M, Baccolini V, Migliara G, Isonne C, Renzi E, Tuñé D, et al. *Acinetobacter baumannii* isolates from COVID-19 patients in a hospital intensive care unit: molecular typing and risk factors. *Microorganisms* 2022; 10: 722.

27. Chan XHS, O’Connor CJ, Martyn E, Clegg AJ, Choy BJK, Soares AL, et al. Reducing broad-spectrum antibiotic use in intensive care unit between first and second waves of COVID-19 did not adversely affect mortality. *J Hosp Infect* 2022; 124: 37-46.

28. Moradi N, Kazemi N, Ghaemi M, Mirzaei B. Frequency and antimicrobial resistance pattern of bacterial isolates from patients with COVID-19 in two hospitals of Zanjan. *Iran J Microbiol* 2021; 13: 769-778.

29. Moreno-Torres V, De Mendoza C, De la Fuente S, Sánchez E, Martínez-Urbistondo M, Herráiz J, et al. Bacterial infections in patients hospitalized with COVID-19. *Intern Emerg Med* 2022; 17: 431-438.

30. Papst L, Luzzati R, Carević B, Tascini C, Gorišek Mikišnik N, Vlahović Palčevski V, et al. Antimicrobial use in hospitalised patients with COVID-19: an international multicentre point-prevalence study. *Antibiotics (Basel)* 2022; 11: 176.

31. Scott H, Zahra A, Fernandes R, Fries BC, Thode HC Jr, Singer AJ. Bacterial infections and death among patients with Covid-19 versus non-Covid-19 patients with pneumonia. *Am J Emerg Med* 2022; 51: 1-5.

32. Zhang H, Zhang Y, Wu J, Li Y, Zhou X, Li X, et al. Risks and features of secondary infections in severe and critical III COVID-19 patients. *Emerg Microbes Infect* 2020; 9: 1958-1964.

33. Liu HH, Yaron D, Piraino AS, Kapeluszni L. Bacterial and fungal growth in sputum cultures from 165 COVID-19 pneumonia patients requiring intubation: evidence for antimicrobial resistance development and analysis of risk factors. *Ann Clin Microbiol Antimicrob* 2021; 20: 69.

34. Hughes S, Troise O, Donaldson H, Mughal N, Moore LS. Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting. *Clin Microbiol Infect* 2020; 26: 1395-1399.

35. De Santis V, Corona A, Vitale D, Nencini C, Potalivo A, Prete A, et al. Bacterial infections in critically ill patients with SARS-2-COVID-19 infection: results of a prospective observational multicenter study. *Infection* 2022; 50: 139-148.

36. Shafran N, Shafran I, Ben-Zvi H, Sofer S, Sheena L, Krause I, et al. Secondary bacterial infection in COVID-19 patients is a stronger predictor for death compared to influenza patients. *Sci Rep* 2021; 11: 12703.

37. Nasir N, Rehman F, Omair SF. Risk factors for bacterial infections in patients with moderate to severe COVID-19: a case-control study. *J Med Virol* 2021; 93: 4564-4569.

38. Gebhard C, Regitz-Zagrosek V, Neuhauser HK, Morgan R, Klein SL. Impact of sex and gender on COVID-19 outcomes in Europe. *Biol Sex Differ* 2020; 11: 29.

39. McClelland EE, Smith JM. Gender specific differences in the immune response to infection. *Arch Immunol Ther Exp (Warsz)* 2011; 59: 203-213.

40. Cullen W, O’Brien S, O’Carroll A, O’Kelly FD, Bury G. Chronic illness and multimorbidity among problem drug users: a comparative cross sectional pilot study in primary care. *BMJ Fam Pract* 2009; 10: 25.

41. White PL, Dhillon R, Healy B, Wise MP, Backs M. Reply to Rodriguez et al and manstrangelo et al. *Clin Infect Dis* 2021; 73(9): e2839-e2841.

42. Vaseghi N, Shariftsooraki J, Khodadadi H, Nami S, Safari F, Ahangarkani F, et al. Global prevalence and subgroup analyses of Coronavirus disease (COVID-19) associated *Candida auris* infections (CAAs): A systematic review and meta-analysis. *Mycoses* 2022; 65: 683-703.

43. Westblade LF, Simon MS, Satlin MJ. Bacterial coinfections in coronavirus disease 2019. *Trends Microbiol* 2021; 29: 930-941.

44. Casalini G, Giacomelli A, Ridolfo A, Gervasoni C, Antinori S. Invasive fungal infections complicating COVID-19: A narrative review. *J Fungi (Basel)* 2021; 7: 921.

45. Salehi M, Ahmadikia K, Badali H, Khodaviaisy S. Opportunistic fungal infections in the epidemic area of COVID-19: a clinical and diagnostic perspective from Iran. *Mycopathologia* 2020; 185: 607-611.

http://ijm.tums.ac.ir

IRAN. J. MICROBIOL. Volume 14 Number 5 (October 2022) 624-635 635